Angiotech Pharmaceuticals (ANP.TO) Buy, Sell…

Angiotech Pharmaceuticals (ANP.TO)

0.00

-0.00 (0.00%)

2 watching

TOP PICK

Surprised that it hasn't moved a little more recently. Should do very well on the royalties in the coated stent market. Trades at 15 X next year's earnings. Building a pipeline as well.

WAIT

Has had a pretty good pullback in the last little while. Their marketer, Boston Scientific, on the other hand has been doing very well. Earnings/revenue are coming in much better than expected but wait for a positive trend to be established.

TOP PICK

Coated stents is probably the biggest area in the medical arena. Have reported good data. Expects their royalty rates to go up this summer.

WAIT

Stents have shown dramatic improvements. Not in a hurry to add money to the sector they are in. A good indicator is to watch Boston Scientific in the US who is marketing their stents. If it goes to a new high, that would be the time to get in.

HOLD

Johnson and Johnson have come back as a competitive threat on their stents. Long-term will be good. Multiple may be a bit rich.

BUY

With Boston Scientific handling sales, you should see a growth. A great story.

DON'T BUY

Was a great stock as a concept stock but when manufacturing starts, the stock falls apart. Model price of $22.

BUY

Down a little bit, but still should make lots of money.

TOP PICK

The numbers four Boston Scientific have been spectacular. They have a better delivery stent. Should have a 70% market share.

TOP PICK

Coated stents have done very well. Boston Scientific just reported that the stents captured 70% of the market and had $98 million in sales. Accelerating momentum. We'll probably earn $.80/.90 this year and double next year.

BUY

A great company and one of Canada's success stories in biotech's. Prefers playing this through Boston Scientific which has better valuation.

BUY

A great product. Tremendously high margins. Should make some money. Growth will be slower than what it has been in the past.

DON'T BUY

Has been a great stock but doesn't think there's any more news for it. Fully valued.

DON'T BUY

Has a problem with intellectual properties in biotech companies and competition, which in their case is Johnson and Johnson.

BUY

Had a good base and broke out in early 2003. It must not break down through $30, but otherwise a good stock. Stop loss of $27/28.

Showing 76 to 90 of 140 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Keith Richards

ValueTrend Wealth Management

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Angiotech Pharmaceuticals (ANP.TO)